Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma

Respiratory syncytial virus (RSV) bronchiolitis is not only the leading cause of hospitalization in U.S. infants, but also a major risk factor for asthma development. While emerging evidence suggests clinical heterogeneity within RSV bronchiolitis, little is known about its biologically-distinct endotypes. Here, we integrated clinical, virus, airway microbiome (species-level), transcriptome, and metabolome data of 221 infants hospitalized with RSV bronchiolitis in a multicentre prospective cohort study. We identified four biologically- and clinically-meaningful endotypes: A) clinical(classic)microbiome(M. nonliquefaciens)inflammation(IFN-intermediate), B) clinical(atopic)microbiome(S. pneumoniae/M. catarrhalis)inflammation(IFN-high), C) clinical(severe)microbiome(mixed)inflammation(IFN-low), and D) clinical(non-atopic)microbiome(M.catarrhalis)inflammation(IL-6). Particularly, compared with endotype A infants, endotype B infants-who are characterized by a high proportion of IgE sensitization and rhinovirus coinfection, S. pneumoniae/M. catarrhalis codominance, and high IFN-alpha and -gamma response-had a significantly higher risk for developing asthma (9% vs. 38%; OR, 6.00: 95%CI, 2.08-21.9; P = 0.002). Our findings provide an evidence base for the early identification of high-risk children during a critical period of airway development. Respiratory syncytial virus (RSV) bronchiolitis during infancy is a major risk factor for asthma development. Here, Raita et al. integrate clinical data with airway microbiome, transcriptome, and metabolome data and identity four endotypes with differential risks for developing asthma.

Automated summary

The study integrated clinical, virus, airway microbiome, transcriptome, and metabolome data of infants hospitalized with RSV bronchiolitis and identified four endotypes with differential risks for developing asthma.